Earnings Call Summary | HeartBeam(BEAT.US) Q4 2023 Earnings Conference
Earnings Call Summary | HeartBeam(BEAT.US) Q4 2023 Earnings Conference
The following is a summary of the HeartBeam, Inc. (BEAT) Q4 2023 Earnings Call Transcript:
以下是HeartBeam, Inc.（BEAT）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
HeartBeam ended 2023 with cash and cash equivalents totaling $16.2 million, allowing operational continuity until early 2025.
到2023年底，HeartBeam的現金及現金等價物總額爲1,620萬美元，從而使運營連續性直至2025年初。
Business Progress:
業務進展：
HeartBeam is enhancing cardiac monitoring with its AIMIGo device that offers high-resolution 3D assessments and a pending FDA clearance aimed by Q2 2024. The company is also developing AI algorithms for advanced diagnostics and predictive capabilities. Future product developments include an on-demand 12-Lead patch and a 12-Lead HeartBeam watch. Finally, their market focus includes both atrial fibrillation and coronary artery disease, reflecting a potential $14 billion total market opportunity in the U.S.
HeartBeam正在通過其AimiGo設備加強心臟監測，該設備提供高分辨率的三維評估，並計劃在2024年第二季度獲得美國食品藥品管理局的批准。該公司還在開發用於高級診斷和預測能力的人工智能算法。未來的產品開發包括按需提供的12導聯補丁和12導聯的HeartBeam手錶。最後，他們的市場重點包括心房顫動和冠狀動脈疾病，這反映了美國潛在的140億美元總市場機會。
More details: HeartBeam IR
更多詳情： HeartBeam 紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。